Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant in early-stage ER+ HER2- breast cancer
NCT04647487Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of imlunestrant in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change From Baseline in Estrogen Receptor Expression at 15 days. Started Apr 2021; status: completed.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04647487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647487.